

Alzheimer’s Disease Was Successfully Treated with Biophoton Generators



P94178

James Z. Liu, Mariola Smotrys, Jessica Jackson, Heather Swartzlander, Seth D. Robinson, Larry Alpert, Helen Y. Gu

First Institute of All Medicines,139 Pittsburgh Road, Butler, PA 16001; Tesla BioHealing, Inc. 1000 Uniqema Blvd, New Castle , DE 19720

Email: James.Liu@FirstAllMed.org

In the treatment group, biophoton generators used daily for four weeks showed significant cognitive improvements: 75% reduced AD Questionnaire severity, 83% improved SF-36 life quality scores, and 94% increased brain bioenergy (P < 0.01). EEG tests indicated fewer missed responses in the treatment group. Caregivers experienced reduced stress and difficulty. No adverse effects were reported. These promising results suggest biophoton therapy as a novel, safe intervention for AD, warranting further investigation.

INTRODUCTION

Alzheimer’s Disease Burden:

Patients: Cognitive decline, emotional impact, physical health issues, loss of independence.

Families: Emotional strain, financial burden, caregiving demands, social isolation.

Society: Economic costs, healthcare resource demands, public health challenges, social services.

Clinical Trial Importance:

Scientific validation, safety assurance, efficacy evaluation, regulatory approval, medical knowledge advancement, patient and family hope, economic impact, ethical responsibility.

Biophotons and AD:

Emerging research suggests biophotons may improve cellular communication and brain function, reducing AD effects through mechanisms like oxidative stress reduction and mitochondrial function improvement.

METHODS

Study Design:

- Randomized, triple-blinded, placebo-controlled.
- 16 moderate/severe AD patients were observed for 4-6 weeks.

Randomization & Blinding:

- Participants assigned randomly to control or treatment groups using a subject number. All study personnel and participants/caregiver were blinded.

Procedure:

- Control group received standard care plus placebo devices for two weeks, then switched to treatment.
- Treatment group used biophoton generators for 8 hours daily for four weeks.

- Assessments included AQ, SF-36, EEG, and bioenergy scans.

Devices:

- Biophoton generators: OTC medical devices.
- Placebo devices: Identical in appearance but inactive.

RESULTS

Experiment 1: Non-AD Volunteers

- Bioenergy and stress levels of 22 participants measured before and after 1 hour using biophoton generators.
- Significant improvements in energy area, balance, and organ imbalance.

Experiment 2: AD Patients

- 7 AD patients used biophoton generators for four weeks.
- Significant increases in whole body bioenergy, nervous system bioenergy, mean bioenergy of 12 meridians, and reduced organ disturbance.

Experiment 3: Brain Bioenergy

- Brain energy levels of AD patients measured using nonlinear quantum scanner after using biophoton generators.
- Significant increases in brain energy levels in 94% patients.

Clinical Efficacy

- AQ Scores:** The 75% of participants showed a 5-point or more improvement in AQ scores after 4 weeks of the biophoton treatment.

Time Point	Mean AQ	SEM	Paired-T Test	P
Baseline	21.25	1.22	(N=12)	
Week4	15.5	0.85	5.8283	0.0001




- MoCA Scores:** Not sensitive for severe AD but some improvements noted.

- SF-36 Scores:** Life quality improved significantly by weeks 3 and 4 of treatment in 83% participants.


CONCLUSIONS

Biophoton therapy significantly improves cognitive function, life quality, and brain bioenergy in moderate/severe AD patients, offering a promising, safe new intervention. Further studies are needed to understand the underlying mechanisms and confirm these findings.

(Results, Continual)



REFERENCES



Many parts of the brain had low bioenergy before biophoton treatment.

Bioenergy level was significantly increased in the brain after the biophoton treatment.

Cecile Moro, et al. The code of light: do neurons generate light to communicate and repair? NEURAL REGENERATION RESEARCH, Vol 17, No. 6, June 2022, 1251

Cecile Moro1, et al. The effect of photobiomodulation on the brain during wakefulness and sleep . 10.3389/fnins.2022.942536

Michael R. Hamblin,. Do Biophotons Play Any Role in Transcranial Photobiomodulation of the Brain? Photobiomodulation, Photomedicine, and Laser Surgery Volume 40, Number 11, 2022

CONTACT




Contact Us:

James.Liu@FirstAllMed.Org

www. Firstallmed.org

info@firstallmed.org



Alzheimer’s Association International Conference